Evidence map›Paper›PMID 28901419›Full record

ArticleMolecular medicine reports2017

MicroRNA‑21 increases cell viability and suppresses cellular apoptosis in non‑small cell lung cancer by regulating the PI3K/Akt signaling pathway.

Tao Wang, Zhenyu Cai, Guolin Hong, Gangsen Zheng, Yu Huang, Shun Zhang, Jinhua Dai

RetractedOpen access · hybridAbstract readRetracted Publication
In one paragraph

Article in Molecular medicine reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.9field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. MiR-21 Expression in Wilms' Tumor.Iranian journal of pathology · 2018
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Tao WangDepartment of Clinical Laboratory, The First Affiliated Hospital of Xiamen University, Fujian Medical University, Xiamen, Fujian 361003, P.R. China.
Zhenyu CaiDepartment of Anesthesiology, The First Affiliated Hospital of Xiamen University, Fujian Medical University, Xiamen, Fujian 361003, P.R. China.
Guolin HongDepartment of Clinical Laboratory, The First Affiliated Hospital of Xiamen University, Fujian Medical University, Xiamen, Fujian 361003, P.R. China.
Gangsen ZhengDepartment of Clinical Laboratory, The First Affiliated Hospital of Xiamen University, Fujian Medical University, Xiamen, Fujian 361003, P.R. China.
Yu HuangDepartment of Clinical Laboratory, The First Affiliated Hospital of Xiamen University, Fujian Medical University, Xiamen, Fujian 361003, P.R. China.
Shun ZhangStem Cell and Regenerative Medicine Laboratory, Ningbo No. 2 Hospital, Ningbo, Zhejiang 315010, P.R. China.
Jinhua DaiDepartment of Clinical Laboratory, Ningbo No. 2 Hospital, Ningbo, Zhejiang 315010, P.R. China.
Fujian Medical University · CNNingbo No. 2 Hospital · CNFirst Affiliated Hospital of Xiamen University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MicroRNA (miRNA/miR), a type of non‑coding RNA molecule, is able to inhibit the expression of target genes at multiple stagess. There are 800‑1,000 known miRNAs in the human genome, which serve important roles in cell proliferation, differentiation, apoptosis and migration. Previous studies have demonstrated that the expression of miR‑21 is upregulated in numerous types of malignant tumor, and that miR‑21 participates in the occurrence and development of tumors via complex regulatory mechanisms. The present study aimed to investigate the association between miR‑21 expression, cell viability and apoptosis in a lung cancer cell line, and to elucidate the potential mechanisms. miR‑21 or small interfering RNA against miR‑21 were transfected into A549 non‑small cell lung cancer cells. The mRNA expression of miR‑21 was confirmed. Cell viability and apoptosis were examined using MTT and flow cytometric assays, respectively. The expression of certain apoptosis‑associated proteins was detected by western blotting. The results of the present study demonstrated that miR‑21 was able to increase the proliferation of A549 cells by inhibiting cellular apoptosis. miR‑21 inhibited apoptosis by modulating the activation of the phosphatidylinositol 3‑kinase/Rac‑α serine/threonine protein kinase (Akt) pathway in A549 cells. Correspondingly, inhibition of Akt decreased the apoptosis of A549 cells in miR‑21 siRNA‑treated cells. Therefore, the results of the present study demonstrated that miR‑21 increased cell viability by inhibiting apoptosis, through regulation of Akt activation. The present study demonstrated that miR‑21 may be involved in the progression of lung cancer and may be a novel therapeutic target for the disease.

Indexed as

A549 CellsApoptosisCarcinoma, Non-Small-Cell LungCell Line, TumorCell MovementCell ProliferationCell SurvivalGene Expression Regulation, NeoplasticHumansLung NeoplasmsMicroRNAsPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktSignal TransductionUp-RegulationMicroRNAsMIRN21 microRNA, humanPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-akt

Identifiers

PMID28901419
PMCPMC5865818
OpenAlexW2753861247

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.